Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis.
about
Recent Insights into Cell Surface Heparan Sulphate Proteoglycans and CancerSyndecans as Cell Surface Receptors in Cancer Biology. A Focus on their Interaction with PDZ Domain ProteinsSyndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and PrognosticationMolecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicineSequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic LandscapesExtracellular matrix as target for antitumor therapySyndecan-1 and Its Expanding List of ContactsInsights into the key roles of proteoglycans in breast cancer biology and translational medicineA novel role for syndecan-3 in angiogenesisThe motile breast cancer phenotype roles of proteoglycans/glycosaminoglycans.Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies.Syndecan-1 regulates vascular smooth muscle cell phenotype.Syndecan-1-Induced ECM Fiber Alignment Requires Integrin αvβ3 and Syndecan-1 Ectodomain and Heparan Sulfate ChainsSyndecan-1 and Syndecan-4 Capture Epidermal Growth Factor Receptor Family Members and the α3β1 Integrin Via Binding Sites in Their Ectodomains: NOVEL SYNSTATINS PREVENT KINASE CAPTURE AND INHIBIT α6β4-INTEGRIN-DEPENDENT EPITHELIAL CELL MOTILITY.Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between αVβ3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesEmerging therapeutic targets in metastatic progression: A focus on breast cancer.VE-cadherin cleavage by ovarian cancer microparticles induces β-catenin phosphorylation in endothelial cellsCell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer.Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow.Heparanase augments insulin receptor signaling in breast carcinoma.Syndecans as modulators and potential pharmacological targets in cancer progression.A cytoplasmic C-terminal fragment of Syndecan-1 is generated by sequential proteolysis and antagonizes Syndecan-1 dependent lung tumor cell migration.Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth.Shed proteoglycans in tumor stroma.Facing the enigma of the vascular network in hepatocellular carcinomas in cirrhotic and non-cirrhotic livers.Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.Insulin-like growth factor axis targeting in cancer and tumour angiogenesis - the missing link.Syndecan-1 increases B-lymphoid cell extravasation in response to HIV-1 Tat via αvβ3/pp60src/pp125FAK pathway.Syndecan-1 knockdown inhibits glioma cell proliferation and invasion by deregulating a c-src/FAK-associated signaling pathway.Dually modified transmembrane proteoglycans in development and disease.Syndecan-1 induction in lung microenvironment supports the establishment of breast tumor metastases.Tumor targeted mesoporous silica-coated gold nanorods facilitate detection of pancreatic tumors using Multispectral optoacoustic tomography
P2860
Q26740617-F090C5DF-CC75-44E6-B815-503C95E6BC93Q26766484-4C97DFE3-E07C-4691-A90F-D0A62D372BE1Q26784262-FEA94D42-24FA-4E41-8AA1-6268BC0B8EFAQ26796247-3640073A-9B0A-4B0B-8012-F57BE28F296DQ26801785-D5696158-60F5-444A-B308-D4DDCC82C67AQ28082018-CACF84F8-2F87-46F7-A091-8C7F4AFC3809Q28084514-26968158-5F8E-41D4-8B5E-598B21AE8179Q28085548-C67BCE8F-43A6-47D7-A8C0-5ADF51BE935AQ29347063-14570CB5-4C9C-47C9-96E6-1F7A7B628517Q34031745-A3266E1D-56E6-4602-9291-FB8392A292B0Q34039967-4A4B2121-5A9B-4561-8073-B056FBAC0FA6Q35108169-3085E17E-2A65-4619-9E93-8AA37D065C6CQ35933767-33E35D9D-6976-4B37-9C1D-208A2E14CF82Q36283542-5D83CC5F-B29F-404B-84EE-27D6EC1C8D42Q36807993-DE8BBD15-8FC0-41D5-94D6-6B43895CB590Q36854062-309A55D9-11F8-4B24-824F-953259FA9597Q36905637-A050E803-CCCD-4208-BA5B-C6A71327C2E6Q37282934-5344D74D-FE22-4CF5-8D65-AA02FBBBAE89Q37499263-255B63C7-1730-4B0C-853C-A5F233537114Q37683359-00988086-BF0B-431B-8375-920F60B67C35Q37746011-EE816202-040A-486F-ADF2-096A1B25F3D9Q38189392-240299D8-C3F9-4219-972D-B61E1C2A5746Q38260615-836F548E-2428-4BA3-835C-3E615BA8F707Q38760595-7B2F1701-B610-43B0-844F-C625DA3E6128Q38882752-DEFA6B41-4B7B-4F0B-8EE5-7AAB707146D8Q38977660-B8AE6B30-1CAC-4218-98F9-E60A1085225CQ38985052-754DEC52-F47B-4986-859A-C2FEAEE65020Q38990201-659685E2-49D8-4528-8DDE-B9425F086211Q40486626-01F4C09B-0300-4C5D-972C-55582404966CQ41093681-A0DD3334-FA1E-46A3-8497-DA67BB285A62Q47240245-87963E96-BF04-435A-892F-212C8E2064C1Q55507840-613FAF0F-4D07-47DD-9201-C89ACA487EE2Q57353110-D21BE2F3-3881-48F4-8062-7489935DEF63
P2860
Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Synstatin: a selective inhibit ...... umorigenesis and angiogenesis.
@en
type
label
Synstatin: a selective inhibit ...... umorigenesis and angiogenesis.
@en
prefLabel
Synstatin: a selective inhibit ...... umorigenesis and angiogenesis.
@en
P2860
P356
P1433
P1476
Synstatin: a selective inhibit ...... umorigenesis and angiogenesis.
@en
P2093
Alan C Rapraeger
P2860
P304
P356
10.1111/FEBS.12160
P407
P577
2013-02-24T00:00:00Z